Dr. Ashwin Pachaatt Vinod
@pachaatt
Liver specialist. Alumnus Dept. of Hepatology-PGIMER Chandigarh/ Dept. of Medicine AIIMS New Delhi/ AIIMS Raipur.
A dream that began years ago has finally come true — Dr. Ashwin P Vinod, MBBS, MD (Medicine), DM (Hepatology) it is! Endless gratitude to Dept. of Hepatology, PGIMER & its incredible faculty for shaping my journey. Thank you all for being part of this dream. @HepatologyPGI
6 mon back, I made this doodle, took a print-out and stuck it on the ceiling just above my bed. Today I am one step closer to that dream. Rank 1, Hepatology INI SS. Cheers to 3 years of residency @ PGI Chandigarh, the Mecca of Hepatology in India. @HepatologyPGI #Hepatology
📢An overview on vascular involvement in chronic liver disease: pubmed.ncbi.nlm.nih.gov/40704070/ Everything on: ➡️ portal vein thrombosis ➡️ PSVD ➡️ haemostasis in cirrhosis ➡️ management of portal hypertension ➡️ challenges of TIPS ➡️ vascular consequences of cirrhosis (PoPH, HPS, AKI)
Early #TIPSS for refractory ascites? > Check MELD, Na, and ascites grade 🌟New evidence from @balcar_lorenz & @salvatore_piano now in @JHEP_Reports If you deal with #cirrhosis, this is worth a look: 👉 shorturl.at/pRl5 #liverX #livertwitter @EASLnews @BavenoCoop
How prokinetics work in the GI tract ⏩💡 #4KMedEd 📸: onlinelibrary.wiley.com/doi/10.1111/nm…
📋Key trials in intermediate stage HCC #ESMOGI25 @myESMO @OncoAlert @realbowtiedoc #cancer #oncology #MedX #HCC
INASL-2025 Chandigarh - 7-10th August, 2025 INASL-AASLD Joint Symposia 9th August, 2025 Register Now- inasl2025.com @drsuniltaneja @docMPK @drnipunverma @doc_arka @naveendandia @drbabupgi @HepatologyPGI @AASLDtweets @AASLDPresident @EASLnews @nagachalasani @GSzaboMD
🌍 AASLD is proud to partner with @INASL_Liver and @EASLnews at the upcoming INASL Conference on Saturday, Aug. 9, for two symposiums on #DILI and #ALD. Click to learn more! inasl.org.i
🌍 AASLD is proud to partner with @INASL_Liver and @EASLnews at the upcoming INASL Conference on Saturday, Aug. 9, for two symposiums on #DILI and #ALD. Click to learn more! inasl.org.i
Join us on Thursday, 31 July at 10:00 am EDT/7:30 pm IST for the joint AASLD/INASL webinar in honor of #WorldHepatitisDay. Register for “International Update on #HepB and #HepC ” at liverlearning.aasld.org/URL/WorldHepat… @INASL_Liver @IDSAInfo @EASLnews @esgvh_escmid @ESCMID @AASLDtweets
@ajay_duseja @shivaramsingh @docMPK @RadhaKDhiman
Join us on Thursday, 31 July at 10:00 am EDT/7:30 pm IST for the joint AASLD/INASL webinar in honor of #WorldHepatitisDay. Register for “International Update on #HepB and #HepC ” at liverlearning.aasld.org/URL/WorldHepat… @INASL_Liver @IDSAInfo @EASLnews @esgvh_escmid @ESCMID @AASLDtweets
Applications are invited for Non-DM Senior Resident (Hepatology) at PGIMER Chandigarh. Join a premier institute for hands-on training focused on ERCP, EUS, advanced liver care & cutting edge research. pgimer.edu.in @ISG_India @INASL_Liver
🧵 10 Rheumatology Diagnoses You Can Make Without a Single Positive Lab Yes — zero lab positivity. Because in rheumatology, clinical pattern is king. #RheumTwitter #MedTwitter #Autoimmune @IhabFathiSulima @Janetbirdope
📢Long-awaited CIRROXABAN is OUT! ➡️RCT ppx rivaroxaban, CP7:10, outcome death/tplt/decomp ➡️primary outcome 27% vs 47% (p=0.058) in AC ➡️similar bleeding, more nonpHTN bleeds in AC, RIV levels 100+ assoc w/bleeds ➡️kPa ⬇️ in AC group #livertwitter journal-of-hepatology.eu/article/S0168-…
📣 Diabetes & Liver Symposium 🗓️ 26 July 2025 | 🕕 6–11 PM 📍 The Royal Plaza, New Delhi Struggling with #MASLD in #diabetes care? Learn real-world strategies, drug choices & guideline-based management from top experts. 📄 Early Free registration: tinyurl.com/4a36fwj5
CIRROXABAN Study is finally here! 🔬 First DB RCT evaluating rivaroxaban in cirrhosis 💡 Complication-free survival benefit in Child‑Pugh B7 (HR 0.26 [95 % CI 0.07–0.90]). ⚠️ Mild bleeding ↑, but no increase in severe events. 📄 journal-of-hepatology.eu/article/S0168-…
Vonoprazan High-dose Dual, Vonoprazan Triple and Rabeprazole Reverse Hybrid Therapies for First-line Treatment of H. pylori Infection: A Multicenter Randomized Trial Hsu, et al. 📕 doi.org/10.14309/ajg.0… @MLongMD @JasmohanBajaj
Hello! Since many were asking for the protein content from brands tested in both Citizens Protein Project One and Two, here they are summarized for you.
Review Article From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury Allegretti et al. #LiverX tinyurl.com/y63vw9rf
Rifaximin- no role in hospitalized or out patients. (Primary prophylaxis) pubmed.ncbi.nlm.nih.gov/37942950/ pubmed.ncbi.nlm.nih.gov/39190719/ @JasmohanBajaj recently reported that even SBP secondary prophylaxis has no role. journals.lww.com/ctg/fulltext/2… pubmed.ncbi.nlm.nih.gov/39235290/
I regret to inform you that rifaximin did not improve survival in this RCT enrolling patients with cirrhosis and ascites
IAP 2025 guidelines on acute pancreatitis
The much awaited IAP 2025 guidelines on Acute Pancreatitis are now out!! 🔥 Fortunate to contribute under the guidance of Prof Pramod Garg. sciencedirect.com/science/articl… @JagannathSoumya @Sudipta20534 @DrLakhtakia @randeeprana90 @DeMadaria
This JAMA patient page covers #GLP1 weight-loss medications, focusing on food craving reduction, blood glucose control, dietary strategies, exercise for muscle retention, and lifestyle changes to prevent weight regain. ja.ma/3GGn5Gr
Everything you want to know about the use of albumin infusions profedu.blood.ca/en/transfusion…